NAMS
Newamsterdam Pharma
$30.22
+$0.58 (+1.96%)Jul 27, 2026
Key metrics
The numbers that frame NAMS today
- Market cap
- $3.53B
- P/E (TTM)
- -14.1
- EV / FCF
- -17.9
- Gross margin
- 100%
- EV / Sales
- 112.7
- ROIC
- -106.3%
- Div yield
- 0%
- Debt / equity
- 0.0
- 52wk Low
- $21.14
- 52wk High
- $42.21
Growth
Revenue and earnings trend for NAMS
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about NAMS
Is Newamsterdam Pharma a good buy?
Hold. Newamsterdam Pharma has strong momentum, but poor quality makes the setup mixed. Growth looks strong, which supports the long-term business case. We think Newamsterdam Pharma is selling at a very high price.
What is the market capitalization of NAMS?
Newamsterdam Pharma's market capitalization is $3.53B.
What is the P/E ratio for NAMS stock?
Newamsterdam Pharma's current P/E ratio is -14.1.
What is the 52-week high for NAMS stock?
The 52-week high for Newamsterdam Pharma is $42.21. The current close of $30.22 is 28.4% below that high.
What is the 52-week low for NAMS stock?
The 52-week low for Newamsterdam Pharma is $21.14. The current close of $30.22 is 43% above that low.
Does NAMS stock pay dividends?
Newamsterdam Pharma does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for NAMS?
Newamsterdam Pharma's Debt / Equity ratio is 0.